Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 13/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 2/20 | 0.31 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30029030 | 1.00 | TRPM5 (0.45) | TRPM5HTR7TRPA1CDK9DYRK1A | |
| SCHEMBL30027964 | 0.79 | HTR7 (0.43) | HTR7KDM4E | |
| SCHEMBL24959005 | 0.79 | HTR7 (0.43) | HTR7KDM4E | |
| SCHEMBL30028670 | 0.79 | HTR7 (0.40) | TRPM5HTR7 | |
| SCHEMBL24958754 | 0.79 | HTR7 (0.40) | TRPM5HTR7 | |
| SCHEMBL24958881 | 0.79 | HTR7 (0.40) | HTR7KDR | |
| SCHEMBL24956474 | 0.79 | HTR7 (0.40) | HTR7HDAC6KDR | |
| SCHEMBL30028274 | 0.77 | HTR7 (0.42) | HTR7CDK9DYRK1ADYRK2 | |
| SCHEMBL24958798 | 0.77 | HTR7 (0.42) | HTR7CDK9DYRK1ADYRK2 | |
| SCHEMBL24958762 | 0.74 | TRPM5 (0.43) | TRPM5TRPA1HDAC6ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117295729-A | Carboxy-benzimidazole GLP-1R modulating compounds | 吉利德科学公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | TRPM5 1457/4885HTR7 280/4885TRPA1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.